Evolving perspectives in reverse cardio-oncology: A review of current status, pathophysiological insights, and future directives

Imran, Shahzeb; Rao, Medha Sridhar; Shah, Muhammad Hamza; Gaur, Aditya; Guernaoui, Abderrahmane El; Roy, Subham; Roy, Sakshi; Bharadwaj, Hareesha Rishab; Awuah, Wireko Andrew

doi:10.1016/j.cpcardiol.2024.102389

Current Problems in Cardiology

2024

DOI: 10.1016/j.cpcardiol.2024.102389

|View full text |Cite

Evolving perspectives in reverse cardio-oncology: A review of current status, pathophysiological insights, and future directives

Shahzeb Imran,

Medha Sridhar Rao,

Muhammad Hamza Shah

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Time Relationship between the Occurrence of a Thromboembolic Event and the Diagnosis of Hematological Malignancies

Kępski,

Szmit,

Lech-Marańda

2024

Cancers

View full text Add to dashboard Cite

Objectives. Venous and arterial thromboembolism (VTE/ATE) often coexist with onco-hematologic diagnosis. This study aimed to assess the time relationship between the diagnosis of VTE/ATE and blood cancers. The second aim was to identify VTE/ATE risk factors related to the type of hematology disease and cardiac history. Methods. A total of 1283 patients underwent cardio-oncology evaluation at the Institute of Hematology and Transfusion Medicine in Warsaw from March 2021 through March 2023 (2 years), and 101 (7.8%) cases were identified with VTE/ATE. Results. ATE compared with VTE significantly occurred more often before the diagnosis and treatment of hematologic malignancy: 33/47 (70.2%) vs. 15/54 (27.8%), p < 0.0001. The risk of a VTE episode is exceptionally high in the first months after the diagnosis of an onco-hematological disease and the initiation of anticancer treatment. The higher frequency of VTE was associated with acute myeloid leukemia (17 cases/270 patients/6.30%/p = 0.055), acute lymphocytic leukemia (7 cases/76 patients/9.21%/p = 0.025), and chronic myeloproliferative disease (7 cases/48 patients/14.58%/p = 0.0003). Only the risk of VTE was significantly increased before (OR = 6.79; 95% CI: 1.85–24.95; p = 0.004) and after diagnosis of myeloproliferative disease (OR = 3.12; 95% CI: 1.06–9.16; p = 0.04). Conclusions. ATEs occur more often than VTE before a diagnosis of blood cancer. The risk of VTE is exceptionally high before and after diagnosis of chronic myeloproliferative disease.

show abstract

Time Relationship between the Occurrence of a Thromboembolic Event and the Diagnosis of Hematological Malignancies

Kępski,

Szmit,

Lech-Marańda

2024

Cancers

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Evolving perspectives in reverse cardio-oncology: A review of current status, pathophysiological insights, and future directives

Cited by 1 publication

References 104 publications

Time Relationship between the Occurrence of a Thromboembolic Event and the Diagnosis of Hematological Malignancies

Time Relationship between the Occurrence of a Thromboembolic Event and the Diagnosis of Hematological Malignancies

Contact Info

Product

Resources

About